Europa Biosite has announced that Bio X Cell has appointed Cambridge Bioscience, a member of Europa Biosite, as its exclusive distributor for the United Kingdom and Ireland.
Polpharma Biologics has announced that it has signed licensing agreements with MS Pharma for the commercialisation of its biosimilar candidates vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) in the MENA region.
Aptamer, the developer of next-generation synthetic binders for the life sciences industry, has announced that it has signed a new therapeutic development agreement with Invizius.
Tasso, a company in patient-centric blood collection, and SheMed, a UK-based women’s healthcare company, have teamed up to deliver safer, more personalised weight loss treatments through convenient at-home diagnostics.
Scenic Biotech, a pioneer in modifier therapies for severe diseases, has announced a license and research agreement with Alnylam Pharmaceuticals to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.
Er-Kim, an international pharma company specialising in the commercialisation of novel therapies, has announced a distribution agreement with CNX Therapeutics to supply selected oncology products across Central & Eastern Europe (CEE) and Türkiye.
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford.
UST, a digital transformation solutions company, has partnered with ThinkBio.Ai, an AI-powered solutions provider for biopharmaceutical and healthcare organisations.
Polpharma Biologics announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialisation of PB016.
After Identiv announced it's partnership with Novanta to streamline adoption of RFID solutions for healthcare and medical device OEMs, European Pharmaceutical Manufacturer spoke to Deepak Prakash, vice president of healthcare at Identiv.
Kling Bio has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its B cell immortalisation and screening platform, Kling-Select.
